At least nine antibacterial compounds are in Phase III trials, but none of the 10 studies of those compounds target the most urgently needed indications: hospital-acquired or ventilator-associated pneumonia (HABP/VABP) and community-acquired bacterial pneumonia (CABP). All the studies include trial sites in the U.S., with the exception of trials for tuberculosis and travelers' diarrhea, which are indications uncommon in the West, and nine of the 10 programs have some exclusion criteria on prior antibiotic use. Companies